The multifaceted impact of complement on atherosclerosis

2022/03/17 by Máté G. Kiss, Christoph J. Binder · 87 citations
Immunology and Microbiology · Medicine · #Biology #Cell biology #Complement component 5 #Complement membrane attack complex #Complement system #Complement system in diseases #Immune system #Immunology #Innate immune system #Pathogenesis #Renal Diseases and Glomerulopathies #Systemic Lupus Erythematosus Research

paper · pdf · doi:10.1016/j.atherosclerosis.2022.03.014

published in Atherosclerosis 351, 29-40 (Elsevier BV)

openalex publication_date 2022/03/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Abstract

As one of the cornerstones of innate immunity, the complement system has long been implicated in the pathogenesis of atherosclerosis. Growing evidence demonstrates the presence of complement activation products in human atherosclerotic plaques, where they can exhibit both protective and proatherogenic properties as supported by numerous experimental findings. While complement initiation resulting in the cleavage of the central complement component C3 appears to have a crucial role in tempering lesion progression by aiding the clearance of apoptotic cells, cascade propagation to the terminal pathway characterized by C5 cleavage and membrane attack complex formation may promote plaque vulnerability. Nevertheless, these assumptions are made based on studies focusing predominantly on systemic, liver-derived complement, whereas it is now evident that almost every cell type can produce complement proteins and the site of synthesis can dictate the function of complement. However, the role of local complement activation in lesion formation remains largely understudied. Here, we review the current literature on complement activation in human atherosclerotic plaques, discuss clinical and genetic associations between complement and cardiovascular disease susceptibility and summarize experimental evidence gained from animal studies. Furthermore, by highlighting recent findings with respect to extrahepatic complement production in the artery wall, we illustrate the necessity to uncover the contribution of local (paracrine, autocrine as well as intracellular) vis-à-vis systemic complement activation to atherosclerotic lesion formation.

Cited by

• Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis
• Apolipoprotein B-containing lipoproteins in atherogenesis
• Molecular Pharmacology of Inflammation Resolution in Atherosclerosis. [europepmc]
• The OSE complotype and its clinical potential. [europepmc]
• Impact of Hydrophilic Modification of Synthetic Dialysis Membranes on Hemocompatibility and Performance. [europepmc]
• Vulnerable Atherosclerotic Plaque: Is There a Molecular Signature? [europepmc]
• Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions. [europepmc]
• ER stress induced immunopathology involving complement in CADASIL: implications for therapeutics. [europepmc]
• Single-cell profiling reveals inflammatory polarization of human carotid versus femoral plaque leukocytes. [europepmc]
• Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. [europepmc]
• Lysophosphatidylglucoside/GPR55 signaling promotes foam cell formation in human M2c macrophages. [europepmc]
• Adipsin in the pathogenesis of cardiovascular diseases. [europepmc]
• ITGB2 is a central hub-gene associated with inflammation and early fibro-atheroma development in a swine model of atherosclerosis. [europepmc]
• Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner. [europepmc]
• The complement system in neurodegenerative diseases. [europepmc]
• Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease. [europepmc]
• Linking peripheral atherosclerosis to blood-brain barrier disruption: elucidating its role as a manifestation of cerebral small vessel disease in vascular cognitive impairment. [europepmc]
• The complement system in lipid-mediated pathologies. [europepmc]
• Complement Immune System in Pulmonary Hypertension-Cooperating Roles of Circadian Rhythmicity in Complement-Mediated Vascular Pathology. [europepmc]
• Alternative Complement Pathway in Carotid Atherosclerosis: Low Plasma Properdin Levels Associate With Long-Term Cardiovascular Mortality. [europepmc]
• Granzyme K activates the entire complement cascade. [europepmc]
• Persistence of a Proteomic Signature After a Hypertensive Disorder of Pregnancy. [europepmc]
• The Interplay Between Immunity, Inflammation and Endothelial Dysfunction. [europepmc]
• AI-Driven Prediction of Cardio-Oncology Biomarkers Through Protein Corona Analysis. [europepmc]
• Inflammation resolution-based treatment of atherosclerosis using biomimetic nanocarriers loaded with specialized pro-resolving lipid mediators. [europepmc]
• Imidazole propionate is a driver and therapeutic target in atherosclerosis. [europepmc]
• Proteolytic profiling of human plasma reveals an immunoactive complement C3 fragment. [europepmc]

Related

• Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats
• Therapeutic regulation of complement activation in extracorporeal circuits and intravascular treatments with special reference to the alternative pathway amplification loop
• Thematic Review Series: The Immune System and Atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis
• Inflammation during the life cycle of the atherosclerotic plaque
• The membrane attack complex drives thrombotic microangiopathy in complement mediated atypical hemolytic uremic syndrome